

FOR IMMEDIATE RELEASE**Silence Therapeutics plc****All resolutions passed at Annual General Meeting**

London, June 18, 2010 – Silence Therapeutics plc (“the Company”) today held its 2010 Annual General Meeting at the Company’s offices at The Royal Institution, 21 Albemarle Street, London, W1S 4BS. All resolutions put to the shareholders at the meeting were passed.

Details of these resolutions can be found in the Notice of the Meeting on the Company’s website: www.silence-therapeutics.com. In addition, the annual report of the Company for the year ended December 31, 2009 has been posted to shareholders and is available on the Company's website.

– Ends –

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. A second, complementary delivery technology known as PolyTran™ uses a library of novel peptide-based biodegradable polycationic polymers for systemic siRNA administration. Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. Silence’s unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The company’s strong and diverse intellectual property portfolio includes exclusive licenses from the University of Massachusetts Medical School on three patent families associated with the Zamore “Design Rules,” which cover broad structural features of siRNA design for more potent next generation siRNA sequences.

Silence Therapeutics is headquartered in London, UK, with research and development activities in Berlin and operations in Redwood City, CA.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

#

For further information, please contact:

Silence Therapeutics

Phil Haworth

(650) 855-1514

p.haworth@silence-therapeutics.com

Vida Communication (on behalf of Silence)

Tim Brons (media)

(415) 675-7400

tbrons@vidacommunication.com

Nomura Code Securities

Richard Potts / Jonathan Senior

020 7776 1200

Stephanie Diaz (investors)

(415) 675-7400

sdiaz@vidacommunication.com